Login to Your Account

FDA Accepts Zealand's GLP-1 Drug Lixisenatide for Review

By Cormac Sheridan
Staff Writer

Wednesday, February 20, 2013
The FDA accepted for review a new drug application for lixisenatide, the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist Zealand Pharma A/S has developed in partnership with Sanofi SA, paving the way for a possible U.S. approval in Type II diabetes by early 2014.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription